Skip to main content

CORRECTION article

Front. Pharmacol., 09 April 2019
Sec. Neuropharmacology
Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.00344
This article is part of the Research Topic Biomarker Exploration in Neuropsychiatry: Understanding of the Pathophysiology and Therapeutic Implications View all 17 articles

This article is a correction to:

  1. Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets

    1. Read original article
\r\nCaroline Brando-TelesCaroline Brandão-Teles1Valria de AlmeidaValéria de Almeida1Juliana S. Cassoli,Juliana S. Cassoli1,2Daniel Martins-de-Souza,,*Daniel Martins-de-Souza1,3,4*
  • 1Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
  • 2Faculdade de Palmas, Palmas, Brazil
  • 3UNICAMP's Neurobiology Center, Campinas, Brazil
  • 4Instituto Nacional de Biomarcadores em Neuropsiquiatria, Conselho Nacional de Desenvolvimento Científico e Tecnológico, São Paulo, Brazil

A Corrigendum on
Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets

by Brandão-Teles, C., de Almeida, V., Cassoli, J. S., and Martins-de-Souza, D. (2019). Front. Pharmacol. 10:186. doi: 10.3389/fphar.2019.00186

The title of the article has been changed from “Oligodendrocytes: Potential of Discovering New Treatment Targets” to “Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: schizophrenia, mechanism of action, proteomics, biomarkers, chlorpromazine, haloperidol, quetiapine, risperidone

Citation: Brandão-Teles C, de Almeida V, Cassoli JS and Martins-de-Souza D (2019) Corrigendum: Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets. Front. Pharmacol. 10:344. doi: 10.3389/fphar.2019.00344

Received: 18 March 2019; Accepted: 19 March 2019;
Published: 09 April 2019.

Approved by:

Frontiers in Pharmacology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2019 Brandão-Teles, de Almeida, Cassoli and Martins-de-Souza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Daniel Martins-de-Souza, ZG1zb3V6YUB1bmljYW1wLmJy; ZGFubXM5MEBnbWFpbC5jb20=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.